Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsTwo Danaher companies — Integrated DNA Technologies (IDT) and Aldevron — have teamed up to launch research-grade Cas9 mRNA products designed to streamline CRISPR-based gene editing workflows. Available in wild-type and high-fidelity formats, the new tools promise better editing efficiency, reduced off-target risk, and a clearer path from early research to clinical-scale manufacturing.
Two genomics powerhouses join forces to simplify CRISPR development
Integrated DNA Technologies (IDT) and Aldevron, both part of Danaher, have launched research-grade S.p. Cas9 mRNA in two formats: wild-type and SpyFi™ high-fidelity. The collaboration combines IDT's CRISPR protein engineering expertise with Aldevron's mRNA manufacturing capabilities, giving researchers a more seamless toolkit for advancing gene editing programs — from early discovery all the way to CGMP-scale manufacturing.
The new Cas9 mRNA is designed to work across multiple cell types, including T cells, iPSCs, and immortalized cells, and is compatible with electroporation, cationic lipids, and lipid nanoparticles (LNPs) — offering flexibility for diverse research applications. Importantly, the mRNA is enzymatically capped, sidestepping certain proprietary capping technologies and reducing licensing complexity for researchers.
Key Takeaways:
Why it matters: As gene therapies inch closer to clinical reality, researchers need tools that are not only high-performing but also scalable and licensing-friendly. This launch addresses a real bottleneck in translational gene editing, helping promising therapies move from bench to bedside faster.
